APO-DORZOLAMIDE SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE)

から入手可能:

APOTEX INC

ATCコード:

S01EC03

INN（国際名）:

DORZOLAMIDE

投薬量:

2%

医薬品形態:

SOLUTION

構図:

DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 2%

投与経路:

OPHTHALMIC

パッケージ内のユニット:

100

処方タイプ:

Prescription

治療領域:

CARBONIC ANHYDRASE INHIBITORS

製品概要:

Active ingredient group (AIG) number: 0128558001; AHFS:

認証ステータス:

APPROVED

承認日:

2010-10-25

製品の特徴

PRODUCT MONOGRAPH
APO-DORZOLAMIDE
DORZOLAMIDE HYDROCHLORIDE OPHTHALMIC SOLUTION
DORZOLAMIDE 2% WEIGHT/VOLUME
STERILE OPHTHALMIC SOLUTION
ELEVATED INTRAOCULAR PRESSURE THERAPY
(TOPICAL CARBONIC ANHYDRASE INHIBITOR)
APOTEX INC.
DATE OF PREPARATION:
150 SIGNET DRIVE
OCTOBER 25, 2010
TORONTO, ONTARIO
M9L 1T9
CONTROL NUMBER:
107589, 141578
_____________________________________________________________________________________________
_APO-DORZOLAMIDE Product Monograph _
_ _
_Page 2 of 20_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..........................................
3
SUMMARY PRODUCT
INFORMATION.........................................................
3
INDICATIONS AND CLINICAL
USE...............................................................
3
CONTRAINDICATIONS
....................................................................................
3
WARNINGS AND
PRECAUTIONS...................................................................
4
ADVERSE REACTIONS
....................................................................................
6
DRUG
INTERACTIONS.....................................................................................
7
DOSAGE AND
ADMINISTRATION.................................................................
8
OVERDOSAGE
...................................................................................................
8
ACTION AND CLINICAL PHARMACOLOGY
...............................................
9
STORAGE AND
STABILITY.............................................................................
10
DOSAGE FORMS, COMPOSITION AND
PACKAGING................................
10
PART II: SCIENTIFIC INFORMATION
..................................................................
11
PHARMACEUTICAL INFORMATION
............................................................
11
CLINICAL
TRIALS.............................................................................................
11
DETAILED
PHARMACOLOGY........................................................................
13
T